StreetAlpha
13F holdings · Q3 2026

Euclidean Capital

New York, NY · files as Euclidean Capital LLC
Know the moment Euclidean Capital filesYou follow Euclidean Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1825034

Euclidean Capital reported 10 stocks worth $324M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VEU (83.2%), INDA (5.3%) and ORIC (4.1%). Compared with Q2 2026, the fund opened new positions in MRLN and sold out of VTV and SRZN.

Latest filing: what Euclidean Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
1 new0 added0 trimmed2 sold outBought about $90K · sold about $113M
New 1
Added 0

None

Trimmed 0

None

Sold out 2

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$324M−26.4% vs last quarter
Stocks held101 new · 2 sold out
Top 5 weight96.8%very concentrated
Turnover35%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
VEU
Vanguard Intl Equity Index F
$269M83.2%3.2MNo change8 of 8
2
INDA
Ishares TR
$17.3M5.3%370KNo change8 of 8
3
ORIC
Oric Pharmaceuticals Inc
$13.3M4.1%989KNo change8 of 8
4
TMS
Teamshares Inc
$8M2.5%1.1MNo change2 of 8
5
FHTX
Foghorn Therapeutics Inc
$5.6M1.7%1.6MNo change8 of 8
6
PMVP
Pmv Pharmaceuticals Inc
$4.4M1.4%2.6MNo change8 of 8
7
SRZN
Surrozen Inc
$2.8M0.9%88KNo change8 of 8
8
ALEC
Alector Inc
$2.4M0.8%1.3MNo change8 of 8
9
TNYA
Tenaya Therapeutics Inc
$613K0.2%1MNo change8 of 8
10
MRLN
Merlin Inc
$90K0.0%48KNew position1 of 8

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
VTV
Vanguard Index Fds
$113M520K
SRZN
Surrozen Inc
$3K171K

Reported value

last 8 quarters
$737MQ4 '24
$266MQ1 '25
$306MQ2 '25
$238MQ3 '25
$369MQ4 '25
$392MQ1 '26
$440MQ2 '26
$324MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Euclidean Capital 13F FAQ

What does Euclidean Capital own?

Euclidean Capital reported 10 stocks worth $324M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VEU (83.2%), INDA (5.3%) and ORIC (4.1%). The table above lists every position in the filing (the top 10 without an account).

What did Euclidean Capital buy and sell in Q3 2026?

Compared with Q2 2026: 1 new positions, 0 added to, 0 trimmed and 2 sold out. New positions include MRLN. It sold all of VTV and SRZN.

When will Euclidean Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Euclidean Capital's portfolio worth?

The Q3 2026 filing reports $324M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.